Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 6/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17103242 | 0.79 | SLC9A1 (0.57) | SLC9A1HCAR3CYP2A6KMOMAPT | |
| SCHEMBL2880296 | 0.78 | SLC9A1 (0.48) | SLC9A1HCAR3CYP2A6MAPTPOLB | |
| SCHEMBL19848207 | 0.76 | SLC9A1 (0.59) | SLC9A1HCAR3KMOMAPTGRM2 | |
| SCHEMBL19848373 | 0.75 | SLC9A1 (0.58) | SLC9A1HCAR3GRM2 | |
| SCHEMBL11388453 | 0.75 | POLB (0.48) | CYP2A6MAPTPOLB | |
| SCHEMBL20529652 | 0.75 | SLC9A1 (0.58) | SLC9A1HCAR3KMOMAPTGRM2 | |
| SCHEMBL19911600 | 0.75 | SLC9A1 (0.58) | SLC9A1HCAR3KMOMAPTGRM2 | |
| SCHEMBL31473638 | 0.75 | SLC9A1 (0.58) | SLC9A1HCAR3KMOMAPTGRM2 | |
| SCHEMBL6187604 | 0.74 | HCAR3 (0.50) | HCAR3CYP2A6 | |
| SCHEMBL6182902 | 0.73 | HCAR3 (0.78) | SLC9A1HCAR3KMOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1247810-B1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6664395-B2 | Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia | PFIZER INC | 2003-12-16 | — | — | US | disclosed |
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1247810-A1 | Novel benzotriazoles anti-inflammatory compounds | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | MAPK1, JAK1, RUNX1 | SLC9A1 1389/4885HCAR3 495/4885PTGER4 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.